secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018790
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics reports Q1 net loss of $53.1M; exa-cel submissions complete in US, EU, UK
--------------------------------------------------------------------------------

- Revenue of $100.0M from Vertex upfront; net loss improved to $53.1M vs $179.2M in Q1 2022.
- Cash and securities $1,889.5M; R&D expenses $99.9M, G&A $22.4M.
- Completed rolling BLAs for exa-cel in SCD and TDT; EMA and MHRA submissions validated.
- Initiated clinical trials for next-gen CAR T candidates CTX112 (CD19) and CTX131 (CD70).
- Appointed Raju Prasad as CFO; Brad Bolzon left board; Vertex deal includes $100M upfront and up to $230M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/0000950170-23-018790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/crsp-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer